Verax

FLOTEK JP3 VERAX® ANALYZER ENABLES FIELD GAS USAGE AT PROFRAC

Retrieved on: 
Wednesday, August 10, 2022
U.S. Securities and Exchange Commission, Energy Independence and Security Act of 2007, Multimedia, Atmosphere, CEO, NYSE, Technology, Securities Exchange Act of 1934, SEC, Verax, Security (finance), EPA, New, Company, Executive, View, Judgement, Tier 4, Tier 2, Water, Risk, Natural gas, FTK, Securities Act of 1933, JP3, Solution, Adoption, Social, Kate Richard

ProFrac's adoption of Flotek's JP3 Verax analyzers is expected to accelerate diesel's replacement with natural gas produced in the field in ProFrac's dual-fuel fleets, thereby simultaneously reducing cost and greenhouse gas emissions while increasing returns to our producer customers and protecting their capital equipment.

Key Points: 
  • ProFrac's adoption of Flotek's JP3 Verax analyzers is expected to accelerate diesel's replacement with natural gas produced in the field in ProFrac's dual-fuel fleets, thereby simultaneously reducing cost and greenhouse gas emissions while increasing returns to our producer customers and protecting their capital equipment.
  • This is a win/win/win for Flotek, ProFrac, and producers," said Chairman and CEO John W. Gibson, Jr.
  • He continued, "current use cases show that maximizing natural gas usage in dual fuel fleets can reduce diesel consumption by 50 70%.
  • "ProFrac's agreement for JP3's sensors allows reliable and consistent gas quality that protects our people and equipment in highly variable field conditions.

DSM acquires Brazil's leading animal nutrition technology company to boost precision services offering

Retrieved on: 
Tuesday, June 7, 2022
Nutrition, DSM (company), Pressure, Animal, EVP, Solution, Intelligence, DSM, Livestock, Farmer, Euronext Amsterdam, Mato Grosso, Technology, Farm, Acquisition, Population, Industry, Verax, Efficiency, Consultant, Agriculture, Fine chemical, Health

HEERLEN, Netherlands, June 7, 2022 /PRNewswire/ -- Royal DSM, a global purpose-led science-based company, announces it has reached an agreement to acquire Prodap, a Brazilian animal nutrition and technology company that combines technology offerings, consulting services, and customized nutritional solutions to drive efficiency and sustainability in animal farming.

Key Points: 
  • HEERLEN, Netherlands, June 7, 2022 /PRNewswire/ -- Royal DSM, a global purpose-led science-based company, announces it has reached an agreement to acquire Prodap, a Brazilian animal nutrition and technology company that combines technology offerings, consulting services, and customized nutritional solutions to drive efficiency and sustainability in animal farming.
  • Prodap combines nutrition, consultancy, and technology services to optimize ruminant farming operations.
  • Ivo Lansbergen, EVP DSM Animal Nutrition & Health, commented: "The need for sustainable animal farming has never been greater or more urgent.
  • Royal DSM is a global, purpose-led company in Health, Nutrition & Bioscience, applying science to improve the health of people, animals and the planet.

FLOTEK ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 RESULTS

Retrieved on: 
Thursday, March 31, 2022
Permian, EBITDA, Administration, Company, Webcast, FTK, Ministry of Education (Malaysia), Marketing, Growth, AIDA, NYSE, SG, Judgement, Forgiveness, Research, SEC, Risk, Atmosphere, Telephone, EST, PPP, U.S. Securities and Exchange Commission, NPT, Consolidated, Senior, Data analysis, Security (finance), Ministry of Research, Innovation and Science, Securities Exchange Act of 1934, Securities Act of 1933, Machine learning, COGS, CST, Income, General officer, Energy Independence and Security Act of 2007, Solution, New, Water, Data, Rationalization, Algorithm, Video game, Management, Ridesharing company, Kate Richard, Social, Verax

Consolidated Revenues: Flotek generated fourth quarter 2021 consolidated revenue of $12.2 million, up 20% from $10.2 million in the third quarter, and generally flat compared to $12.1 million in the fourth quarter 2020.

Key Points: 
  • Consolidated Revenues: Flotek generated fourth quarter 2021 consolidated revenue of $12.2 million, up 20% from $10.2 million in the third quarter, and generally flat compared to $12.1 million in the fourth quarter 2020.
  • Cost of goods sold ("COGS") for the fourth quarter of 2021 was $13.1 million versus $4.0 million for the third quarter 2021 and $23.0 million in the fourth quarter of 2020.
  • Fourth quarter 2021 sales revenues for Chemistry Technologies were $11.6 million, representing a 23% increase from the third quarter 2021 and a 7% increase from the fourth quarter of 2020.
  • Data Analytics recognized fourth quarter 2021 sales revenue of $0.6 million which is a 27% decrease from the third quarter 2021 and a 53% decline from fourth quarter 2020.

Flotek Industries, Inc. Releases New International ATEX/IECEx-Certified Verax ISX/IMX™ Online Analyzers

Retrieved on: 
Thursday, October 28, 2021
Vapor pressure, Technology, Carbon, RVP, NYSE, Atmosphere, New, LLC, Multimedia, Plant, API, Solution, Verax, JP3, Viscosity, ATEX, FTK, Water, Oil

("Flotek" or the "Company") (NYSE: FTK) today announced the release of a new generation of international ATEX/IECEx certified online analyzers.The Verax ISX/IMXanalysers("Verax") are specifically designedto withstand routine exposure to extreme outdoor environments, ambient temperaturesup to 55C/131F and sandstormpollution common to international environments.

Key Points: 
  • ("Flotek" or the "Company") (NYSE: FTK) today announced the release of a new generation of international ATEX/IECEx certified online analyzers.The Verax ISX/IMXanalysers("Verax") are specifically designedto withstand routine exposure to extreme outdoor environments, ambient temperaturesup to 55C/131F and sandstormpollution common to international environments.
  • Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people.
  • A technology-driven, specialty green chemistry and data company, Flotek helps customers across industrial, commercial, and consumer markets improve their Environmental, Social, and Governance performance.
  • Flotek serves downstream, midstream, and upstream customers, both domestic and international.

DSM accelerates its strategic journey to a fully focused Health, Nutrition & Bioscience company

Retrieved on: 
Tuesday, September 14, 2021
People, Verax, Popular Executive Committee of Valencia, DSM (company), Digital technology, Science, Dietary supplement, Acceleration, Food, 2009 Davis Cup, Greenhouse, Ownership, Heart, Carotenoid, Nutrition, New York Mets, IQ Business Group, Animal, Veterinarian, Digital, Financial Oversight and Management Board for Puerto Rico, Climate change, IPCC, Solution, Vitamin, Vitamin D, Agility, DSM, Executive, Legacy Fighting Alliance in 2018, Foodservice, Executive Committee, Euronext Amsterdam, Acquisition, Ovamboland People's Organization, Planet, Fine chemical, Renewable energy, Pharmaceutical industry, Management

DSM, with its strong combination of scientific competences and growing portfolio of nutrition and health solutions, is ideally positioned to capture these opportunities.

Key Points: 
  • DSM, with its strong combination of scientific competences and growing portfolio of nutrition and health solutions, is ideally positioned to capture these opportunities.
  • DSM will become a fully focused Health, Nutrition & Bioscience company
    At the heart of DSM's transformation is the creation of three market-focused Business Groups.
  • DSM's new leadership structure will reflect its strategic vision and the organizational structure of a fully focused Health, Nutrition & Bioscience company.
  • Royal DSM is a global, purpose-led company in Health, Nutrition & Bioscience, applying science to improve the health of people, animals and the planet.

Flotek Announces Second Quarter 2021 Results

Retrieved on: 
Monday, August 9, 2021
Permian, Technology, Data, FTK, U.S. Securities and Exchange Commission, BTEX, Water, Biophysical environment, CDT, Toluene, Securities Exchange Act of 1934, Complex, Sale, PPP, ERC, JP3, Solvent, Atmosphere, Industry, Chemistry, Acquisition, Corporation, Benzene, Hydrocarbon, International, Ownership, New, Webcast, Income, Telephone, Solution, Data analysis, SEC, NYSE, State Administrative Expenses, EBITDA, Forgiveness, Risk, Paycheck Protection Program, Securities Act of 1933, Tax Relief and Health Care Act of 2006, CG, Marketing, Disinfectant, EDT, Depreciation, Verax, Goal, ESG, Security (finance), Judgement, Energy Independence and Security Act of 2007, Company, Resolute, Animal, Video game, Property management, Medical device

HOUSTON, Aug. 9, 2021 /PRNewswire/ --Flotek Industries, Inc. ("Flotek" or the "Company") (NYSE: FTK) today announced second quarter results for the three months ended June 30, 2021.

Key Points: 
  • HOUSTON, Aug. 9, 2021 /PRNewswire/ --Flotek Industries, Inc. ("Flotek" or the "Company") (NYSE: FTK) today announced second quarter results for the three months ended June 30, 2021.
  • Consolidated Revenues:Flotek generated second quarter 2021 consolidated revenue of $9.2 million, up 3.4% from $8.9 million in the second quarter 2020, and was down 22.0% versus $11.8 million in the first quarter 2021.
  • Corporate General & Administrative Expenses (CG&A):Corporate general and administrative expenses for the second quarter of 2021 were $2.9 million, compared to $5.4 million for the second quarter of 2020 and $4.4 million for the first quarter of 2021.
  • Flotek will host a conference call on Tuesday, August 10, 2021, at 8:30 am CDT (9:30 a.m. EDT) to discuss its second quarter results for the three months ended June 30, 2021.

Verax Biomedical Signs Exclusive Agreement with Fisher Healthcare for Distribution of Platelet PGD® Test in U.S.

Retrieved on: 
Monday, August 19, 2019
Medical Supplies, Health, Hospitals, Other Health, Biotechnology, Branches of biology, Transfusion medicine, Biology, Cell biology, Coagulation system, In science, Platelet, Verax, Food and Drug Administration, Verax Biomedical, Fisher Healthcare

Verax Biomedical today announced that it has signed an exclusive agreement with Fisher Healthcare , a large healthcare laboratory product distributor, authorizing the company to distribute its Platelet PGD Test through its channel in the U.S.

Key Points: 
  • Verax Biomedical today announced that it has signed an exclusive agreement with Fisher Healthcare , a large healthcare laboratory product distributor, authorizing the company to distribute its Platelet PGD Test through its channel in the U.S.
  • The agreement with Fisher Healthcare comes as Verax prepares for expected FDA guidance on bacterial risk mitigation strategies for platelets.
  • Were extremely pleased that Fisher Healthcare will make our PGD Test available through its channel, said Jim Lousararian, CEO of Verax.
  • Verax is the producer of the Platelet PGD Test , the only rapid test for bacterial contamination in platelets granted a Safety Measure claim by the FDA.

Blood Centers of America and Verax Biomedical enter into Group Purchasing Agreement for the use of the Verax Platelet PGD® Test

Retrieved on: 
Monday, April 29, 2019
Health, Biotechnology, Hospitals, Pharmaceutical, Branches of biology, Transfusion medicine, Blood products, Cell biology, Coagulation system, Platelet, Science, Verax

A number of BCA members are already users of the Platelet PGD Test and the organization sought an agreement with Verax to expand the products availability to its membership.

Key Points: 
  • A number of BCA members are already users of the Platelet PGD Test and the organization sought an agreement with Verax to expand the products availability to its membership.
  • The Verax Platelet PGD Test improves platelet safety and also allow its users to extend platelet shelf life from 5 to 7 Days .
  • Were pleased that BCA approached us to join in this agreement and to see increasing use of PGD at U.S. blood centers, said Verax CEO Jim Lousararian.
  • Verax is the producer of the Platelet PGD Test , the only rapid test for bacterial contamination in platelets granted a Safety Measure claim by the FDA.

Verax Biomedical and Healthtrust® Purchasing Group Enter Agreement for the Use of the Verax Platelet Pgd® Test

Retrieved on: 
Monday, March 4, 2019
Health, Biotechnology, Hospitals, Pharmaceutical, Branches of biology, Blood products, Transfusion medicine, Cell biology, Coagulation system, Platelet, Science, Verax

Enhancing its ability to accelerate growth and meet existing demand, Verax Biomedical Incorporated announced today that it has entered into a three-year laboratory products agreement with HealthTrust Purchasing Group (HPG) to support member hospitals with the implementation of the Verax Platelet PGD Test (PGD).

Key Points: 
  • Enhancing its ability to accelerate growth and meet existing demand, Verax Biomedical Incorporated announced today that it has entered into a three-year laboratory products agreement with HealthTrust Purchasing Group (HPG) to support member hospitals with the implementation of the Verax Platelet PGD Test (PGD).
  • Many hospitals have implemented the PGD Test to address this risk and participation in this new agreement makes it easier for HPG hospital members to implement PGD.
  • The Verax Platelet PGD test not only improves platelet safety but also offers users the opportunity to move to 7 Day platelet dating .
  • Verax is the producer of the Platelet PGD Test , the only rapid test for bacterial contamination in platelets granted a Safety Measure claim by the FDA.